SVI Honours student wins prize for groundbreaking research in metabolism and obesity

SVI Honours student Yifei Zhu has been awarded the prestigious Richard Larkins Prize, recognising her as the top-performing student in the 2024 Royal Melbourne Hospital Honours Program. The award celebrates academic excellence and outstanding research potential in biomedical science.

Yifei completed her Honours year in the Diabetes and Metabolic Disease Laboratory, where her research focused on the role of the protein SIK3 in the brain and its impact on metabolism. Her project explored the potential of SIK3 as a therapeutic target for obesity, a condition affecting millions globally.

“We tested a SIK3 inhibitor in obese mice,” Yifei explained. “We found that blocking SIK3 pharmacologically could reduce food intake and body fat without affecting lean mass. This provides an exciting proof-of-concept for targeting SIK3 in obesity, potentially offering a new treatment option alongside existing therapies.”

Yifei’s work stood out not only for its academic rigour but also for its potential in tackling major public health issues. The findings may pave the way for new interventions in metabolic disorders, offering hope for improved outcomes in obesity management.

Now embarking on her PhD, Yifei continues her research into SIK3, shifting focus to its roles in inflammation and autoimmunity, particularly in relation to cardiovascular disease and type 1 diabetes.

Yifei’s recognition is a testament to her outstanding academic achievements and commitment to advancing medical science. Her dedication to uncovering the molecular underpinnings of chronic diseases further advances SVI’s mission to improve human health through cutting-edge biomedical research.

“I am honoured to receive the Richard Larkins Honours Prize and am so grateful for the recognition of my work. I’d like to thank my mentors at SVI who’ve inspired me to embark on the next phase of my research, investigating the role of SIK3 in inflammation and autoimmune conditions.”